[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100512853":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":36,"centralContacts":44,"locations":53,"responsibleParty":72,"collaborators":74,"id":80,"slug":81,"hasResults":82,"nctId":83,"briefTitle":84,"officialTitle":85,"acronym":86,"eligibilityCriteria":87,"healthyVolunteers":82,"sex":88,"minAge":89,"maxAge":90,"enrollmentInfo":91,"targetDuration":36,"studyType":94,"phases":95,"briefSummary":97,"conditions":98,"keywords":36,"overallStatus":55,"whyStopped":36,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":109},{"fullName":5,"class":6},"Orygen","OTHER",[8,16],{"label":9,"type":10,"description":11,"interventionNames":12},"Guanfacine extended-release","EXPERIMENTAL","Guanfacine extended-release (target dose 4 mg), once daily for approximately 12 weeks plus treatment as usual",[13,14,15],"Drug: Guanfacine Extended Release Oral Tablet","Behavioral: Residential withdrawal","Behavioral: Engagement with alcohol and other drug services",{"label":17,"type":18,"description":19,"interventionNames":20},"Placebo","PLACEBO_COMPARATOR","Placebo once daily for approximately 12 weeks plus treatment as usual",[14,15,21],"Drug: Placebo",[23,31,37,41],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":28},"DRUG","Guanfacine Extended Release Oral Tablet","Target dose 4 mg daily",[9],[29,30],"Intuniv","Guanfacine XR",{"type":32,"name":33,"description":34,"armGroupLabels":35,"otherNames":36},"BEHAVIORAL","Residential withdrawal","4-14 days in residential withdrawal treatment",[9,17],null,{"type":32,"name":38,"description":39,"armGroupLabels":40,"otherNames":36},"Engagement with alcohol and other drug services","Ongoing engagement with a youth drug and alcohol service for counselling or other support for the duration of the study",[9,17],{"type":24,"name":17,"description":42,"armGroupLabels":43,"otherNames":36},"Placebo capsule taken daily",[17],[45,50],{"name":46,"role":47,"phone":48,"phoneExt":36,"email":49},"Gillinder Bedi, DPsych","CONTACT","+61 3 9966 9100","gill.bedi@orygen.org.au",{"name":51,"role":47,"phone":36,"phoneExt":36,"email":52},"Emily A Karanges, PhD","emily.karanges@orygen.org.au",[54],{"facility":5,"status":55,"city":56,"state":57,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"RECRUITING","Parkville","Victoria","3052","Australia","AU",{"type":62,"coordinates":63},"Point",[64,65],144.95,-37.78333,{"lat":65,"lon":64},[68,69],{"name":46,"role":47,"phone":48,"phoneExt":36,"email":49},{"name":70,"role":47,"phone":48,"phoneExt":36,"email":71},"Holly I Bowman, BPsySc(Hons)","holly.bowman@orygen.org.au",{"type":73,"investigatorFullName":36,"investigatorTitle":36,"investigatorAffiliation":36,"oldNameTitle":36,"oldOrganization":36},"SPONSOR",[75,78],{"name":76,"class":77},"Youth Support and Advocacy Service","UNKNOWN",{"name":79,"class":6},"University of Melbourne","100512853","phase-2-guanfacine-extended-release-for-adolescents-with-cannabis-use-100512853",false,"NCT05957848","Guanfacine Extended-release for Adolescents With Cannabis Use","Guanfacine Extended-release Randomised Controlled Trial for Adolescents With Cannabis usE (GRACE)","GRACE","Inclusion Criteria:\n\n1. 12-25 years of age (inclusive) at consent;\n2. Seeking treatment for cannabis use;\n3. DSM-5 Cannabis Use Disorder, mild, moderate or severe;\n4. Self-reported cannabis use on average at least 5 days\u002Fweek during the 28 days prior to screening with a THC positive urine drug screen on the day of screening; and\n5. Able to provide informed consent (both adequate IQ and English fluency; \\\u003C18-year-olds will provide consent themselves in addition to parent\u002Fguardian consent).\n\nExclusion Criteria:\n\n1. DSM-5 substance use disorder (moderate or severe) except cannabis or nicotine;\n2. Any unstable medical, psychiatric or neurological condition or medical contraindicating study participation;\n3. Diagnosis of a psychotic or bipolar illness;\n4. Acute suicidality as assessed by clinician;\n5. Prescribed antipsychotics, benzodiazepines or other sedative medications, or other medications for the treatment of ADHD. If prescribed antidepressants, the participant must have been on a stable dose for more than 2 weeks at screening;\n6. A history of heart disease or cardiac risk factors (e.g. arrhythmias);\n7. Abnormal liver or thyroid function as indicated by clinically-significant findings on blood tests;\n8. Pregnancy, breast feeding or, if sexually active and able to become pregnant, no effective contraception.\n9. Intention to enter residential rehabilitation after treatment in the YSAS residential withdrawal facility.","ALL","12 Years","25 Years",{"count":92,"type":93},100,"ESTIMATED","INTERVENTIONAL",[96],"PHASE2","A randomized controlled trial to assess the efficacy of extended-release guanfacine to reduce cannabis use frequency in young people with cannabis use disorder following a period of monitored abstinence.",[99],"Cannabis Use Disorder","2025-07-29",{"date":102,"type":103},"2025-07-31","ACTUAL",{"date":105,"type":103},"2023-07-27",{"date":107,"type":93},"2026-06-30",{"name":5,"class":6},1]